Background: Amylin is a calcitonin gene-related peptide family member expressed
| INTRODUCTION
Amylin, member of the calcitonin gene-related peptide (CGRP) family, is a hormone secreted by pancreatic β-cells (Cooper et al., 1987; Westermark, Wilander, Westermark, & Johnson, 1987) , promoting satiety (Lutz, 2005) . It is also expressed in the nervous system, mainly in C-peptidergic neurons of the dorsal root ganglia (DRG) projecting to the spinal dorsal horn (Mulder et al., 1995) , suggesting a possible role in nociception. Amylin crosses the blood-brain barrier (BBB) (Banks & Kastin, 1998; Banks, Kastin, Maness, Huang, & Jaspan, 1995) and binds to several brain areas (Sexton, Paxinos, Kenney, Wookey, & Beaumont, 1994; van Rossum, Menard, Fournier, St-Pierre, & Quirion, 1994) . Amylin-receptors (AmyR) consist of a calcitonin-receptor (CTR) core associated with one receptor activity-modifying protein (RAMP) (Christopoulos et al., 1999; McLatchie et al., 1998; Muff, Buhlmann, Fischer, & Born, 1999) . Calcitonin-receptors exist in embryonic rat DRG and spinal cord (Tolcos, Tikellis, Rees, Cooper, & Wookey, 2003) , and in embryonic and adult mouse spinal cord (Huang, Yang, Chang, & Dun, 2010; Jagger, Gallagher, Chambers, & Pondel, 1999) , and when associated with a RAMP may form a functional AmyR (Cottrell et al., 2005) . Amylin binding sites and CTR expression were described in brain areas implicated in the cognitive-affective component of pain perception or belonging to the descending pain modulatory pathways (Becskei, Riediger, Zund, Wookey, & Lutz, 2004; Sexton et al., 1994; van Rossum et al., 1994) . However, the existence and function of amylin binding sites in the spinal cord and DRG are unrevealed. Studies suggested amylin may have a role in nociception, but results vary according to the pain model and the administration route (Potes, Pestana, Pontes, Caramelo, & Neto, 2016) . Amylin induced analgesic effects in visceral pain, probably associated with a spinal action (Huang et al., 2010) . Intracerebroventricularly (ICV)-administered amylin increased the paw withdrawal latency (PWL) in the hot plate with no effect in the tail flick tests (Bouali, Wimalawansa, & Jolicoeur, 1995; Sibilia et al., 2000) . Conversely, amylin knockout (KO) mice displayed reduced pain responses in the formalin test, suggesting a pronociceptive role in primary sensory neurons (Gebre-Medhin, Mulder, Zhang, Sundler, & Betsholtz, 1998) .
Remarkably, amylin's expression in DRG is altered during chronic pain (Mulder, Zhang, Danielsen, & Sundler, 1997a , 1997b . Sciatic axotomy reduced amylin expression in L4-L5 DRG, suggesting it might be an excitatory neuropeptide (Mulder, Zhang, Danielsen, & Sundler, 1997a) , as also indicated by studies using KO mice (Gebre-Medhin et al., 1998) . However, amylin's role in chronic peripheral neuropathic pain is unknown.
To clarify the role of amylin as a modulator of neuropathic pain, this study evaluated the effects of acute and chronic amylin subcutaneous (SC) administrations on the nociceptive behaviour of rats subjected to the spared nerve injury (SNI) surgery, a model of chronic peripheral neuropathic pain (Decosterd & Woolf, 2000) . The effects of chronic SC administration on the expression of the immediate-early gene c-Fos (Harris, 1998) and phosphorylation of extracellular signal-regulated kinases 1 and 2 (pERK 1/2) (Ji, Baba, Brenner, & Woolf, 1999) were also evaluated in the spinal dorsal horn, along with the density of amylinergic fibres. To assess if amylin's effects in neuropathic pain are mediated by spinal amylin-receptors, amylin and the specific antagonist of amylin-receptors, AC187 (Reidelberger et al., 2004; Young et al., 1994) , were intrathecally (IT) administered.
| METHODS

| Experimental animals
Fifty-five young adult male Wistar rats (Charles River Laboratories, France), weighting between 175 and 225 g at the beginning of the experiments, were housed with temperature, humidity and lighting conditions of 22 ± 2°C, 55% ± 5% and 12-hr light/12-hr dark cycle, respectively. Animals were kept in groups of 2 with free access to food and water and were allowed to adapt to the housing conditions and handling for 2 weeks. The animals' well-being was regularly checked, paying particular attention to the manifestation of signs of stress, illness or poor physical condition caused by surgical procedures or behavioural tests, such as excessive weight loss, dehydration, dirty fur, aggressive social behaviour, low mobility and poor wound healing. The experimental procedures were performed according to the ethical guidelines for the study of experimental pain in conscious animals (Zimmermann, 1983) , the European Communities Council Directive 2010/63/EU and the regulations of local authorities concerning the use of animals for scientific purposes. All procedures were reviewed by the IBMC Animal Ethics Committee and approved by the Portuguese National Authority for Animal Health.
| Drugs
The vehicle used in all experiments was sterile saline solution (0.9% NaCl).
The selected amylin doses (100 µg/Kg and 0.5 µg/µl for acute subcutaneous and intrathecal administrations, respectively; 2 µg Kg -1 hr -1 for chronic SC administration), volumes and time of administration were based on studies in rats and mice regarding the nociceptive and anti-inflammatory amylin actions (Bouali et al., 1995; Clementi et al., 1995; Huang et al., 2010; Potes et al., 2016; Sibilia et al., 2000; Young, 1997) , on transient and sustained anorectic amylin effects after acute and chronic administrations (Lutz, Mollet, | ALMEIDA Et AL. Rushing, Riediger, & Scharrer, 2001; Lutz et al., 1998; Potes & Lutz, 2010) , and on own preliminary data. AC187, derived from salmon calcitonin, acts as a selective competitive antagonist of amylin receptors (Howitt & Poyner, 1997; Young et al., 1994) . The selected dose (3 μg/ μl) used for acute IT administration was based on previous studies (Grabler & Lutz, 2004; Lutz, Tschudy, Rushing, & Scharrer, 2000; Mollet, Gilg, Riediger, & Lutz, 2004; Potes et al., 2016; Reidelberger et al., 2004; Rushing et al., 2001) .
Both amylin and AC187 were kindly provided by Amylin Pharmaceuticals, Inc, USA.
| Study design
Animals were submitted to the SNI surgery (or control SHAM surgery) to induce neuropathic pain. Mechanical allodynia, mechanical hyperalgesia and cold allodynia were assessed by the von Frey, pinprick and acetone behavioural tests, respectively, at days 7, 10 and 14 post-surgery, to confirm the development of neuropathic pain in all animals. At day 14, animals were randomly assigned to four experimental groups in order to determine the effects of an acute SC administration of 100 µg/Kg of amylin (AMY) or of vehicle (VEH; 0.1 ml/100 g of body weight) on nociceptive behaviour. Namely the following groups were assigned: SNI-amylin acute SC (SNI-AMY-SC; n = 6), SNI-vehicle acute SC (SNI-VEH-SC; n = 7), SHAM-amylin acute SC (SHAM-AMY-SC; n = 5) and SHAM-vehicle acute SC (SHAM-VEH-SC; n = 6). The previously mentioned pain behaviour tests were performed at 0 (immediately prior the injection), 30, 60 and 90 min after the SC injection. At the end of the behaviour evaluation, animals were submitted to a minor surgery to implant a subcutaneous mini-osmotic pump for the continuous/chronic (CHR) delivery of 2 µg Kg -1 hr -1 of amylin or 1 µl hr -1 of vehicle for 7 days (days 14-21). Namely the following groups were assigned: SNI-AMY-CHR (n = 8), SNI-VEH-CHR (n = 7), SHAM-AMY-CHR (n = 6) and SHAM-VEH-CHR (n = 6). The effects of chronic systemic amylin or vehicle administration were determined at days 17 and 21, that is 3 and 7 days after the implantation of the mini-osmotic pumps, by the von Frey, pinprick and acetone tests, and the cold plate test was only performed at day 21. Two hours after the last test, animals were perfused, the spinal cord segments L4-5 were collected and preserved for posterior immunohistochemistry reactions, as detailed in Tissue processing and Immunohistochemistry. Spinal cord segments were processed for the evaluation of c-Fos (Harris, 1998) and pERK1/2 (Ji et al., 1999) proteins to evaluate if amylin administration modulated the neuronal response to the nociceptive inputs. To phenotype the cells expressing pERK1/2, double immunofluorescence reactions were performed using markers for neurons (neuronal nuclei antigen-NeuN (Mullen, Buck, & Smith, 1992) ), microglia (αM integrin subunit-CD11b (Ji & Suter, 2007) ) and astrocytes (glial fibrillary acidic protein-GFAP (Sofroniew & Vinters, 2010) ). In order to detect changes in the density of amylinergic fibres, nociceptive fibres and C-nonpeptidergic fibres in the ipsilateral superficial laminae of the L4-5 segments of the spinal cord, double immunofluorescence reactions against amylin, intermediate filament type III (peripherin (Goldstein, House, & Gainer, 1991) ) and isolectin B4 (IB4 (Stucky & Lewin, 1999) ), respectively, were performed. Fourteen days after the induction of neuropathic pain, a separate set of SNI animals was arbitrarily assigned to three groups to determine the effects of an acute IT administration of 25 µg/50 µl of amylin (SNI-AMY-IT; n = 10), of 150 µg/50 µl of the amylin-receptor antagonist AC187 (SNI-AC187-IT; n = 11) or of 50 µl of vehicle (SNI-VEH-IT; n = 6) on neuropathic pain. For this, the von Frey, pinprick and acetone behavioural tests were performed at 0 (right before the injection), 15, 30, 60, 90 and 120 min after the injection.
| Induction of peripheral neuropathic pain
Peripheral neuropathic pain was induced by the spared nerve injury model, as described by Decosterd & Woolf (2000) . Briefly, animals were intraperitoneally (IP) anesthetized with a solution of ketamine hydrochloride (Imalgene, 60 mg/Kg) and medetomidine hydrochloride (Domitor, 0.25 mg/Kg). Incisions were performed along the skin and biceps femoris muscle of the rats' left thigh in order to expose the tibial branch and lead way to the common peroneal branch of the sciatic nerve. Both the tibial and common peroneal branches were tight ligated with a nonabsorbable 5-0 silk thread, and a 2-mm section of these nerves was removed distally to the ligation, while the sural nerve was left intact. Great care was taken to avoid any contact with or stretching of the intact sural nerve. Finally, the muscle and skin were sutured in separate layers with an absorbable polyglycolic acid 4-0 suture. The same surgical procedure was performed for control SHAM groups (n = 12), except that there was no lesion performed to any of the three branches of the sciatic nerve. Pain behavioural tests were carried out one week after the intervention to allow post-surgical recovery and the development of neuropathic pain.
| Pain behaviour assessment
Animals were accustomed to the investigator, to the wire grid of the von Frey, pinprick and acetone tests and to the cold plate apparatus during the light cycle for, at least, one week prior to the behavioural tests. The animals were confined to a transparent chamber on the top of a high metal grid for the von Frey, pinprick and acetone tests and to a similar transparent chamber on the cold plate device, where they could move freely. The behavioural tests were performed in all animals one day prior to the SNI/SHAM surgery (day -1) and on days 7, 10, 14, 17 and 21 post-surgery, in the same order (first-von Frey, second-pinprick and third-acetone) and interspaced by 2-3 min. To minimize hindpaw sensitization, the cold plate test was only executed at day 21 and was the last test to be executed. At the beginning of each of the first three pain behavioural tests, the animals had all four paws firmly based on the grid and the lateral plantar surface of the ipsilateral hindpaw, which is the hypersensitized area innervated by the intact sural nerve, was stimulated. In the cold plate test, all surfaces of the hindpaws were cooled. In order to dissociate stress and pain experience from the metal grid and the cold plate apparatus, some desensitization trials were performed in days in-between test days.
| von Frey
The animal's ipsilateral hindpaw was stimulated with calibrated von Frey monofilaments of ascending force (0.008, 0.02, 0.04, 0.07, 0.16, 0.40, 0.60, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 1.0, 15.0, 26 .0 and 60.0 g; Touch Test Sensory Evaluator kit, Stoelting). Starting from the thinnest hair, each filament was perpendicularly applied five consecutive times until a nociceptive reaction was obtained, such as lifting, shacking or licking the affected area. The hindpaw withdrawal threshold was obtained by the lowest force required to induce a reaction (Tal & Bennett, 1994) .
| Pinprick
A quick and precise ascending movement was made with a blunt needle to indent but not penetrate the ipsilateral hindpaw skin. The animals' response to the painful stimulus (time spent lifting, shaking and/or hindpaw licking) was recorded, with an arbitrary minimal time of 0.5 s (adapted from Tal & Bennett (1994) ).
| Acetone
Using a syringe adapted with a blunt needle, 40 µl of acetone was applied to the lateral plantar surface of the ipsilateral hindpaw. The time that animals spent in licking, shaking and/ or keeping the hindpaw lifted was recorded. If the animals did not respond, a minimum response value of 0.5 s was assumed, considered the normal response (adapted from Choi, Yoon, Na, Kim, & Chung (1994) ).
| Cold plate
The animals were placed on the metal plate of the cold plate apparatus, previously cooled to 10°C, surrounded by an acrylic rectangular chamber that limits the animal's movements (Bioseb, France). The time latency since the animal touched the cooled plate until a pain response was elicited (lifting, shaking and/or hindpaw licking) was recorded by the device. Responses above 100 s were considered normal (absence of pain). A cut-off of 150 s was established to prevent paw sensitization (Allchorne, Broom, & Woolf, 2005 ).
| Implantation of a subcutaneous miniosmotic pump
Animals were anesthetized with isoflurane (5% for induction and 2.5% for maintenance), and a small incision was made in the skin right between the shoulders blades. Then, for the delivery of 2 µg Kg -1 hr -1 of amylin or 1 µl hr -1 of vehicle, a mini-osmotic pump (Alzet #2001, USA) was implanted in the subcutaneous space with the dispenser facing the caudal body region. Finally, the skin was sutured using an absorbable 4-0 thread. Animals were allowed to recover for three days prior to the pain behavioural tests.
| Intrathecal acute injection
The acute intrathecal injection aimed at reaching the lumbar spinal segments and was performed according to our protocol (Adaes et al., 2017) which was adapted from (De la Calle & Paino, 2002; Ossipov, Suarez, & Spaulding, 1988) . Briefly, rats were anesthetized with isoflurane as described above and the rats' abdomen-pelvic region was lifted to create a slight curvature in the vertebral column at vertebral level L5-S1, which was localized using the anterior part of the iliac crest as a tactile reference point for the L6 vertebra. The rats were then gripped firmly by the hip bones with one hand while with the other hand the L5-6 and the L6-S1 intervertebral spaces were identified using the index finger. Animals were injected with 50 µl of amylin (0.5 µg/µl), AC187 (3 µg/µl) or vehicle solution either at the L5-6 or L6-S1 intervertebral space using a 26-gauge needle connected to a 100-µl Hamilton syringe. For this, the needle was introduced through the widest intervertebral space and was lowered until it contacted with the vertebral body and penetrated into the intrathecal space (perceived by a change of resistance). Correct dura puncture and position of the needle tip was verified by a reflexive flick of the tail or a hindpaw flinch. Behaviour was assessed immediately after complete recovery from anaesthesia, which took about 5-10 min.
| Tissue processing
Twenty-one days after SNI/SHAM surgery and two hours after the end of the pain behavioural tests, animals carrying a mini-osmotic pump (CHR groups) were euthanized with an intraperitoneal overdose of sodium pentobarbital (Eutasil
100 mg/Kg) and perfused through the ascending aorta with 250 ml of Tyrode's followed by 750 ml of paraformaldehyde 4% solution. The spinal lumbar segments 4 and 5 were collected, post-fixed for 4 hr at 4°C in the same paraformaldehyde solution and then cryoprotected in a solution of sucrose 30% in phosphate buffer 0.1 M at 4°C for, at least, 48 hr. Using a freezing microtome, spinal cords were transversely cut into 40-µm-thick sections (four sequential series) that were then preserved in a cryoprotectant solution of sucrose 30% dissolved in phosphate buffer 0.1 M and ethylene glycol for posterior immunohistochemistry processing.
| Immunohistochemistry
| c-Fos
One of the four spinal cord series of each animal was immunoreacted against c-Fos protein.
For that, free-floating spinal cord sections were washed in phosphate buffer saline (PBS) 0.1 M, pretreated with 1% hydrogen peroxide in PBS solution for 20 min at room temperature (RT) in order to block the endogenous peroxidase activity and then washed in PBS and in PBS with 0.3% of Triton X-100 (PBST). To minimize background staining, spinal cord sections were pre-incubated with a blocking solution containing 7.5 mg/ml of glycine and 10% of normal swine serum (NSS) in PBST for 90 min at RT. Thereafter, sections were incubated for 48 hr at 4°C with a polyclonal rabbit anti-c-Fos (1:5,000, PC38, clone Ab-5, Calbiochem, Germany) primary antibody solution diluted in PBST with 2% of NSS. Subsequently, sections were washed in a 2% NSS-PBST solution, incubated for 1 hr at RT with a biotinylated swine anti-rabbit immunoglobulin (1:200, E0353, Dako, Denmark) diluted in 2% NSS-PBST solution and then washed in PBST. Afterwards, to amplify the signal, sections were incubated in avidin-biotin-peroxidase complex solution (ABC; 1:200, Vectastain ABC kit, Vector Laboratories, USA) for 1 hr at RT. Spinal cord sections were washed in tris-HCl 0.05 M pH 7.6 and stained with 3,3'-diaminobenzidine tetrahydrochloride hydrate (DAB; D5637, Sigma-Aldrich) chromogen solution (10 mg of DAB in 20 ml of tris-HCl 0.05 M pH 7.6 solution with 5 µl of hydrogen peroxide 30%). Finally, sections were mounted on gelatinecoated slides, dried overnight at 37°C, immersed in xylol (Prolabo, Portugal) and cover-slipped with Entellan (Merck, Germany).
| pERK1/2
A second series of spinal cord sections was immunoreacted to detect the phosphorylated/active forms of ERK1/2 proteins. Except where mentioned, this protocol followed the same steps as the one described above. Sections were incubated with a monoclonal rabbit anti-pERK1/2 (1:500, 4370S, Cell
Signaling, UK) primary antibody diluted in a 2% NSS-PBST solution, for 24 hr at RT. Afterwards, spinal cord sections were incubated for 90 min at RT with biotinylated swine anti-rabbit antibody (1:250, 0353; Dako, Glostrup) and the pERK1/2 signal was obtained using the ABC/DAB method as previously described.
| pERK1/2 and NeuN/CD11b/GFAP
To phenotype pERK1/2 expressing cells, double immunofluorescence reactions were performed using neuronal and glial cell markers. Three double immunofluorescence reactions were performed in L4-5 spinal cord sections of a SNI-VEH-CHR animal. Sections were washed and blocked for 90 min at RT with a solution of 10% of normal horse serum (NHS) diluted in PBST. Then, sections were incubated both with rabbit anti-pERK1/2 (1:250) and with either mouse monoclonal anti-NeuN (1:500, MAB377, clone A60, Millipore), anti-CD11b (1:500, CBL1512Z, clone OX-42, Millipore) or anti-GFAP (1:500, MAB360, clone GA5, Millipore) primary antibodies diluted in a 2% NHS-PBST solution, for 24 hr at RT. After PBST washing, spinal cord sections were incubated for 90 min at RT with donkey anti-rabbit Alexa Fluor-488 (1:1,000, A21206, Molecular Probes) and donkey anti-mouse Alexa Fluor-594 (1:1,000, A21203, Molecular Probes) secondary antibodies prepared in PBST solution. Finally, sections were washed and mounted on gelatine-coated slides, air-dried at 4°C and cover slipped with glycerol-phosphate buffer.
| Amylin/peripherin and IB4
Sections of L4-5 spinal cord segments of one representative animal of each CHR experimental group (SNI-AMY-CHR, SNI-VEH-CHR, SHAM-AMY-CHR and SHAM-VEH-CHR) that received either amylin or vehicle for one week (days 14-21 of SNI/SHAM) were used in two double immunofluorescence reactions. The following protocol was an adaptation of the latter. Briefly, sections were pretreated with a blocking solution of 10% of NHS in PBST for 90 min. Then, spinal cord sections were incubated with rabbit polyclonal anti-amylin (1:2,000, T-4146, Bachem, Germany) or with rabbit polyclonal anti-peripherin (1:1,000, ab99942, Abcam) primary antibody diluted in a 2% NHS-PBST solution for 24 hr at RT. Then, sections were incubated with donkey antirabbit Alexa Fluor-488 (1:1,000, A21206, Molecular Probes) secondary antibody and IB4 Alexa Fluor-568 (1:750, I21412, Molecular Probes), washed and mounted as described before.
| Data analysis
Results are presented as mean ± standard error of the mean (SEM). The software GraphPad Prism 6 was used for the statistical analysis. Data normality was verified by the Kolmogorov-Smirnov test and, whenever the results did not pass the normality test, the nonparametric Kruskal-Wallis or Friedman tests were performed. The results obtained by the pinprick and acetone behavioural tests, as well as the weight gain, of the groups of animals chronically administered with either amylin or vehicle were evaluated by a two-way analysis of variance (ANOVA) with time as repeated-measure, followed by the Fisher's least significant difference (LSD) post hoc test, and were separated in two periods of time. The first, between the day prior to the SNI/SHAM surgery (day -1) and day 14 post-surgery, corresponding to the period of time of neuropathy development and progression (SNI/SHAM surgery and time were used as variables). The results acquired during the second period, between days 17 and 21, were related to the effect of the chronic treatment (amylin/vehicle administration and time as variables). In both periods of time, the results of the von Frey behavioural test were evaluated by the nonparametric Kruskal-Wallis test followed by the Dunn's post hoc test. For the cold plate behavioural test on day 21, the nonparametric Kruskal-Wallis analysis was performed followed by the Dunn's post hoc test.
For the groups of SNI animals acutely treated IT with amylin, AC187 or vehicle at day 14, the development and progression of the neuropathic pain until day 14 was assessed by comparing the results obtained by the von Frey, pinprick and acetone behavioural tests at each time point (days 7, 10 and 14 post-surgery) with the results acquired at the day prior to the SNI surgery (baseline, day -1). For that analysis, the nonparametric Friedman test, followed by Dunn's post-hoc test, was executed. Additionally, the Kruskal-Wallis test was performed to ensure that the results of the three experimental groups were not significantly different from each other at each time point prior to the IT acute administration performed on day 14.
The results of the acute SC and IT administration of amylin, AC187 or vehicle at day 14 were analysed by the Kruskal-Wallis test followed by Dunn's post hoc test to detect significant differences between experimental groups at each time point.
The number of c-Fos positive cells was quantified on the ipsilateral dorsal horn of five L4 and five L5 randomly selected spinal cord sections of the CHR group of animals. Using a light microscope coupled to a lucid chamber (Nikon, Amstelveen), the ipsilateral dorsal horn of each section was outlined on a paper sheet and divided in superficial (laminae I-II), intermediate (laminae III-IV) and deep (laminae V-VI) layers. Positive c-Fos nuclei were identified in the drawing for posterior quantification in each of the three delimitated regions. The average number of L4-5 positive neurons per section for the four experimental groups was determined, and results were presented as the mean ± SEM. To evaluate the effect of the neuropathy (SNI vs. SHAM) and the effect of the treatment (amylin vs. vehicle), a two-way ANOVA followed by the LSD post hoc test was performed.
Images were acquired with a 10× magnification objective using a light microscope (Zeiss Axioskop 40) coupled to a camera and the AxioVision 4.8.2 image software (Carl Zeiss MicroImaging GmbH).
To analyse the expression of phosphorylated ERK1/2 in the superficial dorsal horn of the spinal cord of CHR group of animals, the images of five L4 and five L5 randomly selected sections were captured at 10x magnification by a light microscope (Zeiss Axioskop 40) coupled to an AxioCam MRc5 camera and the AxioVision 4.8.2 image software (Carl Zeiss MicroImaging GmbH). Positive cells for pERK1/2 were quantified in laminae I-II, and the results were presented as the mean ± SEM. The effects of the neuropathy (SNI vs. SHAM) and the treatment (amylin vs. vehicle) were evaluated by the two-way ANOVA followed by the LSD post hoc test.
The images of the double immunofluorescence reactions were acquired at 10x and 20x magnification using a fluorescence microscope (AXIO Imager.Z1) connected to a digital camera with AxioVision 4.6 software.
| RESULTS
| Effect of chronic subcutaneous infusion of amylin
Over the two-week period after the SHAM/SNI surgery (days 7, 10 and 14), SHAM animals exhibited a correct posture of the ipsilateral hindpaw and normal responses to all behavioural tests. On the contrary, SNI animals showed the expected hunched posture of the ipsilateral hindpaw and displayed significantly reduced withdrawal thresholds in the von Frey test and increased response duration in the pinprick and acetone tests, comparatively to the day prior to the induction of the SNI model. There was some interindividual variability among the SNI animals in the pinprick test of mechanical hyperalgesia.
One day before the SHAM/SNI surgery (day -1), the mean ± SEM values of the withdrawal threshold in the von Frey test were 14.8 ± 3.7 g, 27.3 ± 10.4 g, 12.6 ± 2.6 g and 10.9 ± 1.3 g for SHAM-VEH-CHR, SHAM-AMY-CHR, SNI-VEH-CHR and SNI-AMY-CHR groups, respectively. After the surgery, the withdrawal threshold for SHAM groups reduced slightly but remained within normal values until day 21 (3.1 ± 0.6 g and 4.7 ± 1.2 g for SHAM-AMY-CHR and SHAM-VEH-CHR groups, respectively, at day 21). In contrast, the SNI surgery caused a marked decrease in the necessary force to induce the withdrawal of the injured hindpaw, which was significantly lower than that obtained for the respective SHAM control groups at all time points | ALMEIDA Et AL.
(minimal value between 0.008-0.021 g; SNI-AMY-CHR vs. SHAM-AMY-CHR and SNI-VEH-CHR vs. SHAM-VEH-CHR, p < 0.05 or p < 0.01 at different time points). Chronic infusion of 2 µg kg -1 hr -1 of amylin or vehicle produced no alterations on the withdrawal threshold of any of the four test groups (days 17-21) (Figure 1a ). For the pinprick behavioural test, in SHAM control groups, the duration of the pain response induced by the stimulation of the region innervated by the sural branch of the sciatic nerve was approximately 0.5 s for all test days, even during the period of chronic amylin or vehicle administration. SNI groups showed, as expected, significantly higher response duration than the correspondent SHAM groups at almost every time point (SNI-AMY-CHR vs. SHAM-AMY-CHR, p < 0.05 at day 21 and p < 0.01 at day 14; SNI-VEH-CHR vs. SHAM-VEH-CHR, p < 0.05 at day 14, p < 0.01 at days 7 and 21 and p < 0.001 at day 17). Two-way ANOVA analysis revealed a significant effect of SNI surgery (p < 0.001) and of time after surgery (p < 0.05) during the first two-week period. Three days after the beginning of the chronic SC infusion of amylin, a tendency was observed towards a reduction of the response duration in SNI animals (10.3 ± 3.4 s) relative to the SNI-VEH-CHR group (19.9 ± 4.2 s), which was not significant (p = 0.055). Also, two-way ANOVA analysis of the period of time comprising the 17-21 days indicated a significant effect of amylin treatment (p < 0.001) highlighted by the lack of significance in the comparison of SNI-AMY-CHR versus SHAM-AMY-CHR at day 17. At day 21, there was no significant difference between the SNI groups and both SNI groups presented values of response duration that were significantly higher than the respective SHAM control groups (SNI-AMY-CHR vs. SHAM-AMY-CHR, p < 0.05; SNI-VEH-CHR vs. SHAM-VEH-CHR, p < 0.01; Figure 1b) .
One day prior to the SNI/SHAM surgery, the mean values of response duration on the acetone test for all four experimental groups varied between 0.5 and 0.8 s. For the SHAM groups, these values persisted during the entire period of behavioural testing. On the contrary, for SNI animals, there was an abrupt increase in the response duration after SNI surgery (22.6 ± 10.6 and 22.5 ± 6.6 s for SNI-VEH-CHR and SNI-AMY-CHR, respectively, at day 7) that remained stable until day 14 (surgery effect, p < 0.001; time effect, p < 0.01). From then on, a significant and progressive increase in the response duration was observed in SNI animals chronically infused with amylin, with values of 54.5 ± 16.0 and 69.0 ± 26.9 s at days 17 and 21 postsurgery, respectively (amylin treatment effect, p < 0.01). In fact, at day 21, which corresponds to the seventh day of chronic amylin infusion, the obtained values for SNI-AMY-CHR group were significantly higher than those obtained for the SNI group that received vehicle solution (p < 0.05) (Figure 1c) .
In the cold plate test, the mean values of the PWL of SHAM animals were 150 ± 0.0 s (cut-off value). In SNI animal groups, it was observed a slight, nonsignificant, reduction in the PWL to values between 122.8 ± 14.9 and 135.5 ± 14.5 s, which was not different between both SNI groups ( Figure 1d ).
| Effect of acute subcutaneous infusion of amylin
Amylin subcutaneous injection did not induce significant effects in any of the acute pain tests performed, comparing to the respective vehicle controls. In the von Frey behavioural test, the mean values of force that SHAM animals tolerated on the stimulated hindpaw were significantly higher than those of animals with neuropathic pain, at all time points (SHAM-AMY-SC vs. SNI-AMY-SC, p < 0.05; SHAM-VEH-SC vs. SNI-VEH-SC, p < 0.01), varying between 5.2 ± 1.3 g and 8.7 ± 3.5 g, during the 90 min of testing, for SHAM-VEH-SC, and 3.3 ± 1.0 g and 4.4 ± 1.2 g for SHAM-AMY-SC. SNI animals presented withdrawal thresholds of 0.008 ± 0.000 g during the entire test period. There were no changes in the withdrawal thresholds of all four test groups after the acute injection of amylin (Figure 2a) .
In the pinprick test, SNI animals presented statistically higher response duration (varying between 14.1 ± 2.9 and 18.4 ± 5.3 s, in the 90 min of test duration, for SNI-VEH-SC; 12.3 ± 6.9 and 27.2 ± 15.2 s for SNI-AMY-SC) than the respective SHAM control groups (varying between 0.5 ± 0.0, the minimal arbitrary value, and 0.8 ± 0.3 s for SHAM-VEH-SC; 0.5 ± 0.0 s for SHAM-AMY-SC) during the 90 min of behavioural testing (SNI-AMY-SC vs. SHAM-AMY-SC, p < 0.05; SNI-VEH-SC vs. SHAM-VEH-SC, p < 0.05 and p < 0.01). There were no changes after amylin injection (Figure 2b) .
In the acetone test, for SHAM animals, the response duration was maintained at the minimum value of 0.5 ± 0.0 and maximum of 1.2 ± 0.6 s for the SHAM-VEH-SC group and 0.5 ± 0.0 and 1.9 ± 1.1 s for the SHAM-AMY-SC group, during the entire 90 min of behavioural evaluation. The SNI animals responded to the cold stimulus exerted by the acetone drop during a significantly longer period of time (varying between 22.9 ± 8.1 and 39.7 ± 10.4 s for SNI-VEH-SC; 21.0 ± 6.4 and 40.8 ± 15.7 s for SNI-AMY-SC) than the respective SHAM groups (SNI-AMY-SC vs. SHAM-AMY-SC, p < 0.05; SNI-VEH-SC vs. SHAM-VEH-SC, p < 0.01). There were no changes in the response duration after amylin injection (Figure 2c ).
| Effect of acute intrathecal infusion of amylin or AC187
One day prior to the induction of the SNI model, the three groups of SNI animals were tested to determine the baseline values of withdrawal threshold, for the von Frey test, and of response duration, for the pinprick and acetone tests. These animals were then submitted to the same behavioural tests at days 7, 10 and 14 post-surgery to assess the development of mechanical allodynia, mechanical hyperalgesia and cold allodynia.
At day -1, all groups showed high withdrawal thresholds in the von Frey test (6.0 ± 1.2 g for SNI-VEH-IT; 8.2 ± 1.3 g for SNI-AMY-IT; 6.4 ± 0.8 g for SNI-AC187-IT). After the induction of the SNI model, the mean ± SEM values of withdrawal thresholds of the three SNI groups abruptly decreased to minimal values that were maintained until day 14 (between 0.008 ± 0.000 and 0.011 ± 0.003 g; SNI-VEH-IT vs. day -1, p < 0.05; SNI-AMY-IT vs. day -1, p < 0.01; SNI-AC187-IT vs. day -1, p < 0.01 and p < 0.001) (Supporting information Figure S1A ).
In the pinprick test, the baseline response duration of all SNI groups was 0.5 ± 0.0 s, the minimal arbitrary value. The duration of the nociceptive behaviours increased significantly one week after the SNI surgery (19.0 ± 4.6 s for SNI-VEH-IT, vs. day -1 p < 0.05; 18.0 ± 3.5 s for SNI-AMY-IT, vs. day -1 p < 0.01; 24.1 ± 4.4 s for SNI-AC187-IT, vs. day -1 p < 0.001) and remained high until day 14 (SNI-VEH-IT vs. day -1, p < 0.05; SNI-AMY-IT vs. day -1, p < 0.01; SNI-AC187-IT vs. day -1, p < 0.01 and p < 0.001; Supporting information Figure S1B ).
The baseline response duration obtained in the acetone behavioural test was 0.5 ± 0.0 s for the three experimental groups. The time spent in liking, shaking and/or keeping the stimulated hindpaw lifted was significantly increased by day 7 for SNI-AMY-IT and SNI-AC187-IT groups (21.2 ± 7.0 s for SNI-VEH-IT, vs. day -1 p > 0.05; 21.1 ± 4.9 s for SNI-AMY-IT, vs. day -1 p < 0.05; 22.8 ± 4.1 s for SNI-AC187-IT, vs. day -1 p < 0.05). At days 10 and 14, the response duration remained high and statistically different from the values obtained one day before the surgical procedure (SNI-VEH-IT vs. day -1, p < 0.001 at day 10; SNI-AMY-IT vs. day -1, p < 0.01 at day 14 and p < 0.001 at day 10; SNI-AC187-IT vs. day -1, p < 0.05 at day 14 and p < 0.001 at day 10) (Supporting information Figure S1C ).
After the two-week period of induction and development of neuropathic pain, each of the three SNI groups received an acute intrathecal injection of amylin, AC187 or vehicle to assess the effect of direct spinal delivery of these substances in nociceptive behaviour.
For the von Frey test, right before the IT injection of amylin, AC187 or vehicle (0 min), all three SNI groups showed low values of withdrawal thresholds (0.010 ± 0.002 g for SNI-VEH-IT; 0.009 ± 0.001 g for SNI-AMY-IT; 0.011 ± 0.003 g for SNI-AC187-IT). Fifteen minutes after the administration of AC187, the withdrawal threshold of the SNI-AC187-IT group increased significantly in relation to the other two SNI groups (1.3 ± 0.8 g; SNI-AC187-IT vs. SNI-VEH-IT and SNI-AMY-IT, p < 0.05), with subsequent progressive recovery to baseline values 120 min after the injection (0.016 ± 0.006 g). Amylin and vehicle acute IT administration did not produce significant alterations throughout the behavioural evaluation (Figure 3a) .
Initially, in the pinprick test, all SNI experimental groups presented high response duration (20.2 ± 4.6 s for SNI-VEH-IT; 22.6 ± 6.9 s for SNI-AMY-IT; 19.1 ± 3.6 s for SNI-AC187-IT). The IT administration of amylin induced a transient decrease in the pain response duration of SNI animals, as after 30 min the SNI-AMY-IT group displayed statistically lower response duration than the SNI-VEH-IT group (4.7 ± 1.2 s vs. 20.0 ± 5.5 s; p < 0.05), which gradually increased thereafter to values close to the baseline and the vehicle group (16.8 ± 6.1 s at 120 min). The injection of AC187 or vehicle did not significantly alter the response duration of SNI animals submitted to the pinprick test for 120 min (Figure 3b) .
Prior to the IT injection of any substance, all SNI groups presented long response duration to the acetone behavioural test (18.5 ± 5.2 s for SNI-VEH-IT; 26.6 ± 7.5 s for SNI-AMY-IT; 23.2 ± 5.2 s for SNI-AC187-IT). There were no significant alterations in the response duration of SNI animals during the 120 min of behavioural evaluation after both amylin and AC187 IT injections (Figure 3c ).
| Weight gain progression
Until the day of the surgical procedure, all four experimental groups had similar weight gain rates. From the day of the SNI/SHAM surgery to the day 14, both groups of SNI animals gained weight at a significantly slower rate than the respective SHAM control groups (significant interaction effect time-surgery, p < 0.001). Three days after the beginning of chronic SC infusion of 2 µg kg -1 hr -1 of amylin (day 17), there was, as expected, a slight reduction of the weight gain in both SNI and SHAM groups, comparing to the respective vehicle controls, whose weight gain rate progressed without changes. At day 21, the weight gain rate of the amylin infused rats was normalized. Two-way 
| c-Fos expression in the spinal cord
The ipsilateral dorsal horn of the L4-5 spinal cord segments of all four experimental groups showed c-Fos positive neurons (nociceptive-responsive) in laminae I-II, laminae III-IV and laminae V-VI. The higher number of c-Fos positive nuclei was found in the intermediate layers (laminae III-IV) of the dorsal horn for all four groups (42.1 ± 6.2 for SHAM-VEH-CHR; 48.0 ± 5.8 for SHAM-AMY-CHR; 53.8 ± 4.6 for SNI-VEH-CHR; 45.8 ± 5.6 for SNI-AMY-CHR).
There was a significantly higher number of c-Fos expressing neurons per section in both SNI groups (41.5 ± 5.9 for SNI-VEH-CHR; 41.0 ± 5.0 for SNI-AMY-CHR) comparing to both SHAM groups (25.2 ± 5.2 for SHAM-VEH-CHR; 33.0 ± 5.7 for SHAM-AMY-CHR) in the deeper layers of the dorsal horn (laminae V-VI; significant effect of the surgery, p < 0.05). There was also a higher expression of c-Fos in laminae V-VI of SNI-VEH-CHR comparing to SHAM-VEH-CHR that almost reached significance (p = 0.0513) (Figure 4 ).
| pERK1/2 phosphorylation in the spinal cord
There were pERK1/2 labelled cells bilaterally in laminae I-II of the dorsal horn of the L4-5 segments of the spinal cord. The numbers of ipsilateral pERK1/2 positive cells were 14.2 ± 1.3 in SHAM-VEH-CHR and 15.5 ± 2.2 in SHAM-AMY-CHR. SNI animals that received vehicle solution presented a slightly higher number of pERK1/2 positive cells (18.2 ± 0.9) than both SHAM groups. However, that difference was not statistically relevant. On the contrary, the group of SNI animals that was chronically treated with amylin showed a significant increase in the number of positive pERK1/2 cells (22.8 ± 2.2) when compared to SHAM-VEH-CHR and SHAM-AMY-CHR groups (significant effect of the surgery, p < 0.01) ( Figure 5 ). The positive pERK1/2 cells of the superficial dorsal horn of the spinal cord, detected with DAB chromogen solution, exhibited a fusiform body with few extensions (Figure 5a-d) .
To further investigate whether these cells were neurons, microglia or astrocytes, three double immunohistochemistry reactions were performed for pERK1/2 and NeuN, CD11b or GFAP, respectively. pERK1/2 labelling was predominantly detected encircling neuronal nuclei in an area corresponding to the cells' cytoplasm (Figure 6a and b) . Moreover, it was not detected any colocalization of pERK1/2 with CD11b ( Figure 6c ) or GFAP cell markers (Figure 6d ).
| Modulation of amylin expression in the spinal cord
There was a decrease in amylin labelling in the ipsilateral superficial dorsal horn of the L4-5 spinal cord segments as compared to the contralateral dorsal horn. This decrease was equally detected in the medial region of the ipsilateral superficial dorsal horn of SNI animals that were chronically treated with vehicle (Supporting information Figure S2E ) or amylin (Supporting information Figure S2G ), but not in SHAM animals (Supporting information Figure S2A and C). However, it was not clear if the reduction in amylin labelling in SNI animals was due to the decrease in the expression of amylin by the C-peptidergic fibres or due to the degeneration of the C-peptidergic fibres themselves. Therefore, in order to detect signs of degeneration of primary afferent fibres induced by the SNI model, double immunohistochemistry reactions were performed for amylin (in green; Supporting information Figure S2A , C, E and G) or type III intermediate filament (peripherin, in green; Supporting information Figure S2B, D, F and H) and the detection of Cnonpeptidergic fibres by the isolectin B4 (IB4, in red). Both the SNI-VEH-CHR (Supporting information Figure S2F) and SNI-AMY-CHR (Supporting information Figure S2H ) groups showed a clear lack in peripherin and IB4 labelling in the medial region of the superficial layers of the dorsal horn, which was not observed in SHAM animals treated chronically with amylin or vehicle (Supporting information Figure  S2B and D).
| DISCUSSION
Acute and chronic effects of amylin administration were assessed in the SNI model. All SNI rats developed allodynia and hyperalgesia, commonly observed during chronic neuropathic pain, in contrary to SHAM animals (Decosterd & Woolf, 2000) . Cold hyperalgesia was not detected in SNI animals, probably due to the hunched posture of the injured hindpaw that prevented the full contact of the paw's sural innervated area with the cold plate. Whereas acute SC amylin injection did not change the nociceptive thresholds of SNI rats, prolonged SC amylin administration significantly and progressively increased the paw withdrawal duration in the acetone test, indicative of cold allodynia aggravation. Chronic amylin administration produced a slight and transient anorectic effect, showing that amylin was successfully delivered while not significantly affecting the animals' appetite. The neuropathy itself reduced the rate of weight Amylin may act at the spinal cord, where CTR and RAMP are expressed, in rats (Tolcos et al., 2003) and mice (Huang et al., 2010; Jagger et al., 1999) . The existence of amylin immunoreactivity in the spinal cord of adult mice (Huang et al., 2010; Mulder et al., 1995) further supports this hypothesis. However, subcutaneously delivered amylin may cross the BBB (Banks & Kastin, 1998; Banks et al., 1995) and act at supraspinal levels having amylin binding sites and CTR expression (Becskei et al., 2004; van Rossum et al., 1994) . Brain areas involved in the cognitive-affective component of pain and/or belonging to the descending pain modulatory pathways (Maeda, Tsuruoka, Hayashi, Nagasawa, & Inoue, 2009; Neugebauer, Li, Bird, & Han, 2004) are activated by subcutaneous amylin and may play a role in amylin-mediated nociceptive effects (Potes et al., 2016; Rowland, Crews, & Gentry, 1997) . Here, a transient antinociceptive effect was detected, with attenuation of mechanical hyperalgesia 30 min after intrathecal amylin injection into the spinal segments receiving innervation from the hindpaw. In apparent contradiction, antagonism of AmyR by intrathecal AC187 delivery significantly increased the von Frey threshold, indicating a brief amelioration of mechanical allodynia. Thus, endogenous amylin may play a pronociceptive role in animals with mechanical allodynia by targeting AmyR in the spinal cord. However, pharmacological amylin doses may ameliorate mechanical hyperalgesia by also targeting spinal AmyR. Since SNI animals showed minimal measurable values of withdrawal thresholds to von Frey filaments prior to amylin administration, it was impossible to assess a probable worsening of mechanical allodynia, remaining unknown whether IT-amylin affects mechanical allodynia and hyperalgesia differently.
Our recent studies in the formalin pain model also showed unexpected similar antinociceptive effects upon IT administration of amylin or AC187. The presence of CTR in DRG of rats embryos (Tolcos et al., 2003) and RAMP mRNA in adult mice (Cottrell et al., 2005; Huang et al., 2010) suggests there are amylin binding sites in primary afferent fibres innervating the skin. However, mRNA for CTR, the core AmyR, was not found in mice foetuses' skin (Jagger et al., 1999) . Hence, the existence of both CTR and RAMP mRNA in the spinal cord and in DRG (Cottrell et al., 2005; Huang et al., 2010; Tolcos et al., 2003) suggests AmyR do not exist in peripheral terminals but may rather be present in both spinal projection neurons and presynaptically on the primary afferents' central branches targeting the dorsal horn. Here, they possibly act as auto-receptors on C-peptidergic fibres controlling amylin's availability and release on laminae I-II, promoting receptor recycling, as RAMP3 promotes receptor trafficking (Bomberger, Parameswaran, Hall, Aiyar, & Spielman, 2005) , but may also exist on Aβ-fibres, which may be related with AC187-induced amelioration of allodynia. The existence of such distinct AmyR systems (to be published) may explain the seemingly incongruent effects of IT-amylin and IT-AC187. Furthermore, the different effects following IT-amylin and SC amylin should be associated with the site of action, as for other neuropeptides like CGRP. While IT-CGRP produces hyperalgesia (Sun et al., 2004) , ICV-CGRP induces antinociception (Candeletti & Ferri, 1990) .
Chronic neuropathic pain induces c-Fos expression in dorsal horn nociceptive-responsive neurons (Yamazaki, Maeda, Someya, & Wakisaka, 2001) . In this study, SNI animals exhibited a significantly higher number of c-Fos positive neurons than SHAM animals in L4-5 ipsilateral laminae V-VI. This region is a primary target of Aδ nociceptive fibres and Aβ-fibres that transmit innocuous inputs (Basbaum, Bautista, Scherrer, & Julius, 2009; Costigan, Scholz, & Woolf, 2009) and is more relevant to chronic pain mechanisms, while laminae I-II, which receive input from Aδ and C nociceptive fibres, are more implicated in acute pain. In neuropathic pain, the nociceptors' activation threshold is lower and spontaneous activity occurs (Costigan et al., 2009) , partly leading to the allodynia experienced by SNI animals. A high number of c-Fos expressing neurons was also detected in the dorsal horn of SHAM animals, probably due to neuronal activation elicited upon behavioural tests. c-Fos expression was not significantly affected by amylin treatment in SNI animals, but it was slightly augmented in SHAM animals, suggesting amylin is likely to modulate the spinal neuronal circuitry activity differently in animals with and without neuropathy.
The involvement of pERK1/2 in the maintenance of chronic neuropathic pain is well established (Geranton, Tochiki, Chiu, Stuart, & Hunt, 2010; Ma & Quirion, 2005; Song et al., 2005) . SNI animals receiving amylin chronically presented a significantly higher number of pERK1/2-positive cells than both SHAM groups, suggesting amylin may trigger the ERK1/2 cascade under neuropathic conditions. Amylininduced activation of the ERK1/2 cascade in the area postrema is implicated in its anorectic effects (Potes, Boyle, Wookey, Riediger, & Lutz, 2012) . Thus, it may also be responsible for mediating amylin-related effects in nociception. Taken together, data suggest that the increase in ERK1/2 phosphorylation, promoted by chronic SC amylin administration, may be related to its effect on the aggravation of cold allodynia in SNI rats. Furthermore, the pERK1/2-positive cells detected in the dorsal horn superficial laminae exhibited a fusiform body with few extensions, suggesting a neuronal phenotype. This was confirmed by pERK1/2 labelling, which predominantly surrounded the nuclei of neurons and did not co-localize with microglia or astrocytes cellular markers, supporting the idea that pERK1/2 cascade is involved in chronic pain modulation in neuronal pathways (Borges, Berrocoso, Mico, & Neto, 2015; Borges, Berrocoso, Ortega-Alvaro, Mico, & Neto, 2013) . In our study, the animals' affected hindpaw was repeatedly stimulated at specific days after the SNI surgery and SNI animals were tested 2 hr before sacrifice. Therefore, it is possible that the induction of ERK1/2 phosphorylation in superficial dorsal horn neurons is the result of both prolonged and acute stimulation of the animals' injured hindpaw. Amylin may have an effect on fibre sensitization, leading to an increased number of pERK1/2-positive neurons.
Decreases in the density of nociceptive fibres immunoreactive for CGRP and substance P, and of C-nonpeptidergic fibres (IB4-positive), in the medial region of the ipsilateral dorsal horn superficial laminae, the area innervated by the axotomized tibial branch of the sciatic nerve, have been reported in nerve injury models (Lee, Siegel, & Oaklander, 2009) . Unilateral transection of the sciatic nerve caused a decrease in amylin expression in L4-5 DRG and in the density of amylinergic fibres in the ipsilateral superficial dorsal horn, suggesting amylin could act as an excitatory peptide (Mulder et al., 1997a) . The finding of reduced pain responses in amylin KO mice further supported this hypothesis (Gebre-Medhin et al., 1998) . Here, a reduction in the density of amylin-positive fibres was also detected, possibly reflecting a compensatory mechanism of the nociceptive system, as reported for other excitatory neuropeptides, to prevent an amylin-induced worsening of cold allodynia. Such hypothesis was not fully supported by our study as the decrease in amylin and IB4 labelling was observed both in SNI animals treated chronically with either amylin or vehicle, but not in SHAM animals. Furthermore, the decrease in nociceptive fibres (peripherin) in the dorsal horn region receiving afferents from the axotomized tibial branch, observed exclusively in SNI animals, suggests a partial denervation of the superficial dorsal horn induced by axotomy of the two branches of the sciatic nerve, rather than a specific modulation of amylin expression by the system or by amylin treatment.
As a conclusion, chronic amylin administration worsened cold allodynia in SNI animals, suggesting a pronociceptive role of amylin in neuropathic pain. As this was not observed after IT-amylin administration, such pronociceptive action is most likely supraspinally mediated. Small changes in c-Fos expression indicate that amylin is likely to modulate the activity of the spinal neuronal circuitry. The increase in pERK1/2 may be associated with the increase of cold allodynia in these animals. The decreased double labelling of IB4 with amylin or peripherin in SNI animals indicates the occurrence of fibre degeneration, restricted to the ipsilateral side, in laminae I-II region receiving afferents from the tibial branch. Acute IT blockade of the amylin-receptor ameliorated mechanical allodynia, suggesting spinal AmyR are sensitive to acute pharmacological manipulation in this pain condition and that endogenous spinal amylin release may play a pronociceptive role in neuropathic pain via spinally located AmyR.
Overall, amylin seems to be pronociceptive in neuropathic pain possibly by acting at supraspinal levels of the nervous system, whereas spinally mediated amylin effects are more complex due to the existence of endogenous amylin release and putatively distinct AmyR spinal systems.
